Changes of Optical Quality During the Peak of the Covid-19 Pandemic

Changes of Optical Quality During the Peak of the Covid-19 Pandemic From November 2022 to January 2023 in China

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05882383

Enrollment

110

Registered

2023-05-31

Start date

2022-11-25

Completion date

2023-01-20

Last updated

2023-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Wavefront Aberration, SARS-CoV-2

Keywords

optical quality

Brief summary

To explore whether cornea structure, and optical quality are affected by the covid-19 infection.

Detailed description

Participants with healthy corneas admitted to Tianjin Eye Hospital from November 25 to January 20, 2022 were followed up . At the end of the follow-up, the investigators recorded in detail whether the patients had undergone real-time reverse transcriptase polymerase chain reaction (covid-19 RT-PCR tests) testing, testing time and results. The presence of PCR-positive during follow-up is considered to be covid-19 infection; PCR-Negative and no symptoms of infection during the follow-up period are considered not infected; participants with symptoms but no PCR test were excluded from the study.Participants were divided into three groups according to the RT-PCR results and the presence or absence of symptoms of infection during follow-up. pentacam (Pentacam HR, Oculus, Wetzlar, Germany) was performed during follow-up and the results were recorded,and the data was statistically managed and compared.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 32 Years

Healthy volunteers

Yes

Inclusion criteria

Included Criteria 1. Best corrected visual acuity (BCVA) ≥ 20/20; 2. No other eye diseases except myopia and astigmatism; 3. The cornea was transparent, and there was no cloud or pannus; 4. No clinical manifestation of Eye disease or systemic disease;

Exclusion criteria

1. corneal disease; 2. ocular trauma; 3. Pregnant and lactating women;

Design outcomes

Primary

Measure	Time frame	Description
The value of cornea aberration	1 months	The value of aberration data from pentacam during follow-up were compared, including coma, spherical aberration, defocus, and astigmatism
The value of cornea backscatter	1 months	The value of cornea backscatter from pentacam during follow-up were compared, including anterior layer，central layer and posterior
The value of cornea thickness	1 months	The value of cornea thickness from pentacam during follow-up were compared, includig the thinnest point, apex of the cornea.

Countries

China

Outcome results